Previous work on the subclones within Escherichia coli ST131 predominantly involved isolates from Western countries. This study assessed the prevalence and antimicrobial resistance attributed to this clonal group. A total of 340 consecutive, non-duplicated urinary E. coli isolates originating from four clinical laboratories in Hong Kong in 2013 were tested. ST131 prevalence among the total isolates was 18.5 % (63/340) and was higher among inpatient isolates (23.0 %) than outpatient isolates (11.8 %, P<0.001), and higher among isolates from patients aged ≥65 years than from patients aged 18–50 years and 51–64 years (25.4 vs 3.4 and 4.0 %, respectively, P<0.001). Of the 63 ST131 isolates, 43 (68.3 %) isolates belonged to the H30 subclone, whereas the remaining isolates belonged to H41 (n = 17), H54 (n = 2) and H22 (n = 1). All H30 isolates were ciprofloxacin-resistant, of which 18.6 % (8/43) belonged to the H30-Rx subclone. Twenty-six (41.3 %) ST131 isolates were ESBL-producers, of which 19 had blaCTX-M-14 (12 non-H30-Rx, two H30-Rx and five H41), six had blaCTX-M-15 (five non-H30-Rx and one H30-Rx) and one was blaCTX-M-negative (H30). In conclusion, ST131 accounts for a large share of the antimicrobial-resistant E. coli isolates from geriatric patients. Unlike previous reports, ESBL-producing ST131 strains mainly belonged to non-H30-Rx rather than the H30-Rx subclone, with blaCTX-M-14 as the dominant enzyme type.
ArvandM., MoserV., PfeiferY.2013; Prevalence of extended-spectrum-β-lactamase-producing Escherichia coli and spread of the epidemic clonal lineage ST131 in nursing homes in Hesse, Germany. J Antimicrob Chemother 68:2686–2688 [View Article][PubMed]
BanerjeeR., JohnsonJ. R.2014; A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131. Antimicrob Agents Chemother 58:4997–5004 [View Article][PubMed]
BanerjeeR., JohnstonB., LohseC., ChattopadhyayS., TchesnokovaV., SokurenkoE. V., JohnsonJ. R.2013a; The clonal distribution and diversity of extraintestinal Escherichia coli isolates vary according to patient characteristics. Antimicrob Agents Chemother 57:5912–5917 [View Article][PubMed]
BanerjeeR., RobicsekA., KuskowskiM. A., PorterS., JohnstonB. D., SokurenkoE., TchesnokovaV., PriceL. B., JohnsonJ. R.2013b; Molecular epidemiology of Escherichia coli sequence type 131 and its H30 and H30-Rx subclones among extended-spectrum-β-lactamase-positive and -negative E. coli clinical isolates from the Chicago region, 2007 to 2010. Antimicrob Agents Chemother 57:6385–6388 [View Article][PubMed]
ClermontO., JohnsonJ. R., MenardM., DenamurE.2007; Determination of Escherichia coli O types by allele-specific polymerase chain reaction: application to the O types involved in human septicemia. Diagn Microbiol Infect Dis 57:129–136 [View Article][PubMed]
ClermontO., ChristensonJ. K., DenamurE., GordonD. M.2013; The Clermont Escherichia coli phylo-typing method revisited: improvement of specificity and detection of new phylo-groups. Environ Microbiol Rep 5:58–65 [View Article][PubMed]
ColpanA., JohnstonB., PorterS., ClabotsC., AnwayR., ThaoL., KuskowskiM. A., TchesnokovaV., SokurenkoE. V. et al.2013; Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis 57:1256–1265 [View Article][PubMed]
HoP. L., YipK. S., ChowK. H., LoJ. Y., QueT. L., YuenK. Y.2010; Antimicrobial resistance among uropathogens that cause acute uncomplicated cystitis in women in Hong Kong: a prospective multicenter study in 2006 to 2008. Diagn Microbiol Infect Dis 66:87–93 [View Article][PubMed]
JohnsonJ. R., MenardM., JohnstonB., KuskowskiM. A., NicholK., ZhanelG. G.2009; Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother 53:2733–2739 [View Article][PubMed]
JohnsonJ. R., TchesnokovaV., JohnstonB., ClabotsC., RobertsP. L., BilligM., RiddellK., RogersP., QinX. et al.2013; Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli.. J Infect Dis 207:919–928 [View Article][PubMed]
JohnsonJ. R., ClermontO., JohnstonB., ClabotsC., TchesnokovaV., SokurenkoE., JunkaA. F., MaczynskaB., DenamurE.2014; Rapid and specific detection, molecular epidemiology, and experimental virulence of the O16 subgroup within Escherichia coli sequence type 131. J Clin Microbiol 52:1358–1365 [View Article][PubMed]
KudinhaT., JohnsonJ. R., AndrewS. D., KongF., AndersonP., GilbertG. L.2013; Escherichia coli sequence type 131 as a prominent cause of antibiotic resistance among urinary Escherichia coli isolates from reproductive-age women. J Clin Microbiol 51:3270–3276 [View Article][PubMed]
LafolieJ., Nicolas-ChanoineM. H., GrenouilletF., HocquetD., BertrandX.2014; Prevalence of Escherichia coli sequence type 131 and its H30 subclone among E. coli isolates in a French hospital. Int J Antimicrob Agents 44:466–468 [View Article][PubMed]
Leflon-GuiboutV., BlancoJ., AmaqdoufK., MoraA., GuizeL., Nicolas-ChanoineM. H.2008; Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. J Clin Microbiol 46:3900–3905 [View Article][PubMed]
MatsumuraY., YamamotoM., NagaoM., HottaG., MatsushimaA., ItoY., TakakuraS., IchiyamaS.Kyoto-Shiga Clinical Microbiology Study Group2012; Emergence and spread of B2-ST131-O25b, B2-ST131-O16 and D-ST405 clonal groups among extended-spectrum-β-lactamase-producing Escherichia coli in Japan. J Antimicrob Chemother 67:2612–2620 [View Article][PubMed]
NaseerU., SundsfjordA.2011; The CTX-M conundrum: dissemination of plasmids and Escherichia coli clones. Microb Drug Resist 17:83–97 [View Article][PubMed]
PeiranoG., PitoutJ. D.2014; Fluoroquinolone-resistant Escherichia coli sequence type 131 isolates causing bloodstream infections in a Canadian region with a centralized laboratory system: rapid emergence of the H30-Rx sublineage. Antimicrob Agents Chemother 58:2699–2703 [View Article][PubMed]
PeiranoG., van der BijA. K., FreemanJ. L., PoirelL., NordmannP., CostelloM., TchesnokovaV. L., PitoutJ. D.2014; Characteristics of Escherichia coli sequence type 131 isolates that produce extended-spectrum β-lactamases: global distribution of the H30-Rx sublineage. Antimicrob Agents Chemother 58:3762–3767 [View Article][PubMed]
PettyN. K., Ben ZakourN. L., Stanton-CookM., SkippingtonE., TotsikaM., FordeB. M., PhanM. D., Gomes MorielD., PetersK. M. et al.2014; Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A 111:5694–5699 [View Article][PubMed]
PriceL. B., JohnsonJ. R., AzizM., ClabotsC., JohnstonB., TchesnokovaV., NordstromL., BilligM., ChattopadhyayS. et al.2013; The epidemic of extended-spectrum-β-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx. MBio 4:e00377–13 [View Article][PubMed]
ShinJ., KimJ., WieS. H., ChoY. K., LimS. K., ShinS. Y., YeomJ. S., LeeJ. S., KweonK. T. et al.2012; Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact. Microb Drug Resist 18:169–175 [View Article][PubMed]
TchesnokovaV., BilligM., ChattopadhyayS., LinardopoulouE., AprikianP., RobertsP. L., SkrivankovaV., JohnstonB., GilevaA. et al.2013; Predictive diagnostics for Escherichia coli infections based on the clonal association of antimicrobial resistance and clinical outcome. J Clin Microbiol 51:2991–2999 [View Article][PubMed]
WirthT., FalushD., LanR., CollesF., MensaP., WielerL. H., KarchH., ReevesP. R., MaidenM. C. et al.2006; Sex and virulence in Escherichia coli: an evolutionary perspective. Mol Microbiol 60:1136–1151 [View Article][PubMed]